Curi RMB Capital’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.04M | Sell |
12,975
-2,840
| -18% | -$234K | 0.02% | 438 |
|
|
2025
Q4 | $1.35M | Buy |
15,815
+1,999
| +14% | +$164K | 0.02% | 405 |
|
|
2025
Q3 | $1.07M | Sell |
13,816
-4,992
| -27% | -$390K | 0.02% | 410 |
|
|
2025
Q2 | $1.47M | Buy |
18,808
+13,232
| +237% | +$987K | 0.03% | 365 |
|
|
2025
Q1 | $404K | Sell |
5,576
-12,262
| -69% | -$878K | 0.01% | 402 |
|
|
2024
Q4 | $1.32M | Sell |
17,838
-5,457
| -23% | -$382K | 0.03% | 308 |
|
|
2024
Q3 | $1.54M | Sell |
23,295
-347,136
| -94% | -$25.2M | 0.03% | 301 |
|
|
2024
Q2 | $34.2M | Sell |
370,431
-7,899
| -2% | -$699K | 0.82% | 30 |
|
|
2024
Q1 | $36.2M | Buy |
378,330
+1,878
| +0.5% | +$158K | 0.83% | 28 |
|
|
2023
Q4 | $28.7M | Buy |
376,452
+1,566
| +0.4% | +$109K | 0.88% | 29 |
|
|
2023
Q3 | $26M | Buy |
374,886
+1,471
| +0.4% | +$118K | 0.89% | 26 |
|
|
2023
Q2 | $35.2M | Sell |
373,415
-5,650
| -1% | -$491K | 1.16% | 21 |
|
|
2023
Q1 | $31.4M | Buy |
+379,065
| New | +$29.8M | 1.1% | 23 |
|
|
2022
Q4 | – | Sell |
-423,193
| Closed | -$35M | – | 475 |
|
|
2022
Q3 | $35M | Sell |
423,193
-20,482
| -5% | -$1.97M | 1.3% | 13 |
|
|
2022
Q2 | $42.2M | Sell |
443,675
-13,292
| -3% | -$1.38M | 1.45% | 12 |
|
|
2022
Q1 | $53.8M | Sell |
456,967
-59,457
| -12% | -$6.67M | 1.7% | 7 |
|
|
2021
Q4 | $66.9M | Sell |
516,424
-8,083
| -2% | -$943K | 2.02% | 3 |
|
|
2021
Q3 | $59.4M | Sell |
524,507
-6,184
| -1% | -$706K | 1.95% | 5 |
|
|
2021
Q2 | $55M | Sell |
530,691
-5,994
| -1% | -$565K | 1.84% | 6 |
|
|
2021
Q1 | $44.9M | Buy |
536,685
+15,621
| +3% | +$1.32M | 1.66% | 8 |
|
|
2020
Q4 | $47.5M | Buy |
521,064
+36,469
| +8% | +$3.03M | 1.74% | 4 |
|
|
2020
Q3 | $38.7M | Sell |
484,595
-7,491
| -2% | -$584K | 1.67% | 8 |
|
|
2020
Q2 | $34M | Buy |
492,086
+1,055
| +0.2% | +$75K | 1.5% | 11 |
|
|
2020
Q1 | $30.9M | Buy |
491,031
+16,395
| +3% | +$1.18M | 1.47% | 9 |
|
|
2019
Q4 | $36.9M | Sell |
474,636
-16,425
| -3% | -$1.28M | 1.03% | 12 |
|
|
2019
Q3 | $36M | Sell |
491,061
-5,781
| -1% | -$406K | 0.95% | 12 |
|
|
2019
Q2 | $30.6M | Sell |
496,842
-10,311
| -2% | -$623K | 0.77% | 19 |
|
|
2019
Q1 | $32.3M | Sell |
507,153
-7,782
| -2% | -$444K | 0.82% | 11 |
|
|
2018
Q4 | $26.3M | Buy |
514,935
+7,749
| +2% | +$392K | 0.67% | 21 |
|
|
2018
Q3 | $29.4M | Buy |
507,186
+8,616
| +2% | +$421K | 0.71% | 20 |
|
|
2018
Q2 | $24.2M | Sell |
498,570
-5,214
| -1% | -$243K | 0.58% | 34 |
|
|
2018
Q1 | $23.4M | Sell |
503,784
-10,479
| -2% | -$455K | 0.6% | 26 |
|
|
2017
Q4 | $19.3M | Buy |
514,263
+415,758
| +422% | +$15.3M | 0.5% | 40 |
|
|
2017
Q3 | $3.59M | Buy |
98,505
+228
| +0.2% | +$8.7K | 0.09% | 292 |
|
|
2017
Q2 | $3.87M | Buy |
98,277
+65,727
| +202% | +$2.4M | 0.11% | 261 |
|
|
2017
Q1 | $1.02M | Buy |
32,550
+450
| +1% | +$14.1K | 0.04% | 300 |
|
|
2016
Q4 | $1M | Sell |
32,100
-39,900
| -55% | -$1.29M | 0.05% | 250 |
|
|
2016
Q3 | $2.89M | Buy |
+72,000
| New | +$2.71M | 0.16% | 159 |
|
Other funds holding EW
VCM
VPM
Curi RMB Capital's EW Position: Q1 2026 in Review
Curi RMB Capital reduced its Edwards Lifesciences (EW) stake by 18% in Q1 2026, selling an estimated $234K and leaving 12,975 shares worth $1.04M. The position accounts for 0.02% of the portfolio, ranked #438.
Curi RMB Capital first reported a position in EW in Q3 2016 and has held it in 38 quarters since. The position peaked at $66.9M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Curi RMB Capital held 12,975 shares of Edwards Lifesciences worth $1.04M as of Q1 2026.
- Curi RMB Capital sold 2,840 Edwards Lifesciences shares in Q1 2026, an estimated $234K.
- Edwards Lifesciences made up 0.02% of Curi RMB Capital's portfolio in Q1 2026, its #438 holding.
- Curi RMB Capital first reported a position in Edwards Lifesciences in Q3 2016 and has held it in 38 quarters since.
- Curi RMB Capital's Edwards Lifesciences position peaked at $66.9M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Curi RMB Capital's 13F filing for Q1 2026, filed 15 May 2026.